-

Blackstone Launches BMACX – Blackstone Private Multi-Asset Credit and Income Fund

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced the launch of Blackstone Private Multi-Asset Credit and Income Fund (BMACX), the firm’s first private multi-asset credit interval fund (the “Fund”). Investors can now access BMACX through select registered investment advisers.

BMACX aims to provide individual investors with a one-stop, private multi-asset credit solution designed to access strategies across Blackstone’s leading $465 billion credit platform. The Fund offers ticker execution with daily subscriptions, quarterly liquidity, and low investment minimums with capital invested immediately.

“We believe BMACX can be a powerful core portfolio building block to tap the expanding credit markets,” said Heather von Zuben, Chief Executive Officer of BMACX. “It brings the full breadth of Blackstone’s credit platform to individuals in what we see as an investor friendly structure.”

“We will aim to deliver high quality, diversified income with lower volatility than traditional fixed income products by investing across a diverse range of compelling credit assets,” said Dan Oneglia, Chief Investment Officer of BMACX. “We believe this multi-strategy approach positions investors to take advantage of attractive relative value, particularly in dynamic market environments.”

BMACX will invest across a diverse range of credit assets, including private corporate credit, asset based and real estate credit, structured credit, and liquid credit, seeking to deliver attractive and stable income through a monthly distribution while managing risk.

BMACX builds on Blackstone’s leadership position delivering private credit solutions to individual investors, with dedicated vehicles focused on direct lending available since 2018.

Blackstone announced that BMACX was declared effective by the U.S. Securities and Exchange Commission in March. More information is available at www.bmacx.com.

About Blackstone Credit & Insurance
Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

About Blackstone Private Wealth
Blackstone Private Wealth was established to answer the growing demand for Blackstone products from high-net worth investors. Partnering with many of the world’s largest private banks and wealth management firms as well as family offices, Blackstone’s Private Wealth team packages and delivers the full breadth of Blackstone’s alternative product capability to these firms and their clients and provides ongoing product and advisor support, as well as education and training around alternatives.

Forward-Looking Statements
Certain information contained in this communication constitutes “forward looking statements” within the meaning of the federal securities laws. These forward-looking statements can be identified by the use of forward-looking terminology, such as “outlook,” “indicator,” “believes,” “expects,” “potential,“ “continues,” “may,” “can,” “will,“ “could,” “should,” “seeks,” “approximately,” “predicts,“ “intends,” “plans,” “estimates,” “anticipates”, “confident,” “conviction,“ “identified” or the negative versions of these words or other comparable words thereof.

These may include financial estimates and their underlying assumptions, statements about plans, objectives and expectations with respect to future operations, statements regarding future performance, statements regarding economic and market trends and statements regarding identified but not yet closed investments. Such forward-looking statements are inherently subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in such statements. BMACX believes these factors also include but are not limited to those described under the section entitled “Risk Factors” in its prospectus, and any such updated factors included in its periodic filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this document (or BMACX’s prospectus and other filings). Except as otherwise required by federal securities laws, BMACX undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This press release must be read in conjunction with the BMACX prospectus in order to fully understand all the implications and risks of an investment in BMACX. This press release is neither an offer to sell nor a solicitation of an offer to buy securities. An offering is made only by the prospectus, which should be read carefully before investing and is available at www.bmacx.com. Before investing you should carefully consider BMACX’s investment objectives, risks, charges and expenses. This and other information is in BMACX’s prospectus.

An investment in the Fund involves a high degree of risk. There is no assurance that the Fund will achieve its investment objectives. An investment in the Fund is suitable only for investors who can bear the risks associated with limited liquidity. Shares of the Fund are not listed on any securities exchange and the Fund does not expect any secondary market will develop for the shares. The Fund intends to utilize leverage and may utilize leverage to the maximum extent permitted by law for investment and other general corporate purposes, which will magnify the potential for loss on amounts invested in the Fund. Please see the prospectus for details of these and other risks.

The Fund is distributed by Blackstone Securities Partners L.P. BMACX is a newly formed investment company with no operating or performance history that shareholders can use to evaluate the Fund.

Contacts

Thomas Clements
Thomas.Clements@blackstone.com
(646) 482-6088

Blackstone

NYSE:BX

Release Versions

Contacts

Thomas Clements
Thomas.Clements@blackstone.com
(646) 482-6088

More News From Blackstone

Blackstone Infrastructure Completes Acquisition of Safe Harbor

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that funds managed by Blackstone Infrastructure (“Blackstone”) have completed their acquisition of Safe Harbor Marinas (“Safe Harbor”), the largest marina and superyacht servicing business in the United States, from Sun Communities, Inc. (NYSE: SUI) for $5.65 billion. Heidi Boyd, a Senior Managing Director in Blackstone’s infrastructure business, said, “We’re pleased to close this transaction and look forward to working with Safe...

Blackstone Real Estate to Acquire 6M SF Industrial Portfolio Developed by Crow Holdings for $718M

NEW YORK & DALLAS--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Crow Holdings, a leading real estate investment and development firm, today announced that Core+ funds affiliated with Blackstone Real Estate have agreed to acquire a 95 percent stake in an industrial portfolio developed by Crow Holdings for $718 million. Crow Holdings and its partners will retain 5 percent ownership. The portfolio consists of 25 Class A buildings totaling 6 million square feet and is predominantly located in high-ba...

Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture,...
Back to Newsroom